Adult Dosing

Nausea/vomiting

• 200 mg IM q8 hrs or q6 hrs

• Dosage should be adjusted on the basis of indication for therapy, severity of symptoms and the response of the patient
• The injectable form is for intramuscular administration only; it is not recommended for intravenous use

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Postoperative nausea and vomiting
• Nausea associated with gastroenteritis

• Hypersensitivity to any of the ingredients of the product
• Pediatric patients

• N/A

Renal Dose Adjustment (Based on CrCl)

• <70 mL/min: Consider decreasing dose or increasing dosing interval

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• For IM use only; not for IV administration
• Antiemetics may make diagnosis of appendicitis more difficult
• Potential for drowsiness; advise patients not to operate motor vehicles or other dangerous machinery until their individual responses have been determined
• Concomitant use of alcohol may result in an adverse drug interaction
• Restore body fluids and electrolyte balance and treat underlying causative disease
• Elderly patients with renal impairment may need decreased doses or increased dosing interval
• Avoid use in children with uncomplicated vomiting. Extrapyramidal symptoms occurring secondary to trimethobenzamide may be confused with CNS symptoms of an undiagnosed primary disease responsible for vomiting
• Limit use to prolonged vomiting of known etiology
• Avoid use in children whose signs and symptoms could represent Reye's syndrome

Cautions: Use cautiously in

• Patients who have recently received other CNS-acting agents
• Alcohol use
• Dehydration
• Electrolyte abnormalities
• Debilitated patients
• Geriatric Population

Pregnancy Category:C

• Safety in pregnancy or in nursing mothers has not been established

Breastfeeding: Safety unknown

• CV: Hypotension, prolonged QT interval
• CNS: Parkinson-like symptoms, mood depression, disorientation, headache, drowsiness, opisthotonos, dizziness, seizures, coma
• EENT: Blurred vision
• GI: Diarrhea, xerostomia
• HEMA: Blood dyscrasias
• HEPA: Jaundice, cholestasis
• LOCAL: Local pain, burning, stinging, redness and swelling (after injection)
• MUSC: Muscle cramps
• MISC: Hypersensitivity reactions

• Antiemetic; exact mechanism of action unknown; it has direct affect on chemoreceptor trigger zone (CTZ), an area in the medulla oblongata by inhibiting stimuli at CTZ
• Metabolized by liver; CYP450: unknown
• Renally excreted: 30-50% (primarily unchanged); urine
• Half-life: 7-9 hrs

US Trade Name(s)

• Tigan

US Availability

trimethobenzamide (generic)

• INJ: 100 mg/mL (2 mL cartridges)

Tigan

• INJ: 100 mg/mL (2, 20 mL vials)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Gastrointestinal

Antiemetics

Anticholinergic Antiemetics